UC Davis Veterinary Clinical Trials

Assessing a New Drug to Treat Heart Failure in Dogs with Myxomatous Mitral Valve Disease

Please bring your dog with congestive heart failure directly to the UC Davis VMTH Emergency Room!

Myxomatous mitral valve disease is the most common cardiac disease and the leading cause of congestive heart failure in dogs. Reducing blood pressure is one strategy to help manage these patients. By reducing blood pressure, the heart can move blood forward more effectively, reducing fluid accumulation in the lungs that can result from this condition. However, available medications for this health emergency are extremely limited and currently available drugs often have extreme price volatility, low availability or unwanted side effects. Researchers will conduct a small clinical trial to evaluate the use of a new drug clevidipine to reduce blood pressure in client-owned dogs admitted to hospital. Finding a safe, affordable alternative drug that is readily available may help improve survival of critically ill canine patients requiring urgent care for heart failure.

Drug - Treatment

Circulating DNA in cats with hypertrophic cardiomyopathy and cardiogenic arterial thromboembolism

Help us look for a screening test to prevent clot formation in cats

Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats. About 20% of cats will develop clinical signs due to HCM. Of these complications, the most devastating is cardiogenic arterial thromboembolism (clot formation), otherwise known as, “saddle thrombus”, which is one of the most distressing emergencies for cat owners. This disease is complicated by the fact that most cats that develop saddle thrombus appear healthy and do not have heart murmurs. Veterinarians currently have limited abilities to test and treat cats at the greatest risk of forming saddle thrombus. For this reason, we hope to look for protein markers and free circulating DNA in the blood of cats with HCM and saddle thrombus. Free circulating DNA has been shown in humans, mice and dogs to promote clot formation and can be used as a treatment target. We, therefore, hope to further understand these findings by seeing if free circulating DNA in cats contribute to saddle thrombus in cats with HCM. This information will enable us to establish a screening test that will guide clinicians in identifying cats at risk of clot formation.

Observational
Any, age > 1 year old

Understanding the genetics causing subvalvular aortic stenosis in Bullmastiffs

Help us find out what genes cause subvalvular aortic stenosis in Bullmastiffs!

Subvalvular aortic stenosis (SAS) is the second most common heart defect diagnosed in dogs, and the Bullmastiff breed is over-represented in incidence of SAS. Moderate and severely affected cases are at risk for developing severe cardiac complications, and have an average lifespan of 19 months. Furthermore, there is no surgical treatment available that results in an increased life expectancy for affected cases. The aim of this study is to identify genes/variants associated with SAS in Bullmastiffs that can be used to develop a genetic test.

Other - Genetic Study
Any, age None specified

What are the Effects of Pimobendan on Hypertrophic Cardiomyopathy in Cats?

Help us Look at a Treatment for Hypertrophic Cardiomyopathy in Cats!

Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats and we do not have a good understanding of how to best treat this devastating disease. One drug, pimobendan, has been shown to have significant clinical benefits in cats with HCM, but more studies are needed to evaluate exactly how this drug affects heart function. The purpose of this clinical trial is to evaluate the effects of pimobendan on heart function in cats affected with HCM, which will help us make with better treatment recommendations for cats with this disease.

Drug